Moleculin Biotech Announces Preclinical Data Showing Annamycin Antitumor Activity In Pancreatic Cancer Is Immune-Mediated

Moleculin Biotech, Inc. (NASDAQ: MBRX) announced preclinical data at the AACR Conference on Pancreatic Cancer indicating that its lead drug candidate, Annamycin, exhibits antitumor activity in pancreatic cancer that is partially mediated by CD8+ T cells. This suggests that Annamycin may not only directly kill cancer cells but also enhance immune response against tumors typically resistant to treatment. The findings could support potential combination therapies, particularly given the immune-modulating properties of the company's WP1066 program.